Vyvanse Cost in Missouri: Prices, Insurance, and Savings in 2026

What Vyvanse Actually Costs at Missouri Pharmacies

The gap between Vyvanse's sticker price and what Missouri residents pay out of pocket is wide. Takeda's manufacturer list price remains $390 per month for brand-name Vyvanse, a figure that has not meaningfully changed since late 2024. But generic lisdexamfetamine, which the FDA authorized in August 2023, has compressed cash-pay pricing dramatically.

Cash-Pay Pricing Across Missouri

Across Missouri retail pharmacies in 2026, the average cash-pay price for a 30-day supply of lisdexamfetamine lands at roughly $35 per month. Prices vary by pharmacy chain, city, and dose strength. A patient filling 70 mg capsules at a large chain in St. Louis or Kansas City may see slightly lower pricing than someone using an independent pharmacy in a rural county.

Why List Price and Cash Price Diverge

The $390 figure reflects Takeda's wholesale acquisition cost for brand-name Vyvanse. Pharmacy benefit managers negotiate rebates, and generic competition from manufacturers like Alvogen and Teva has driven retail pricing below $50 at most Missouri locations. Patients paying cash should always ask the pharmacist for the generic price, not the brand price. The FDA label for Vyvanse confirms that generic lisdexamfetamine is bioequivalent, meaning therapeutic outcomes are identical [1].

Dose and Price Relationship

Lisdexamfetamine is available in capsule strengths from 10 mg to 70 mg. In most Missouri pharmacies, cash-pay pricing does not vary significantly across dose strengths for the generic. This differs from some stimulants where higher doses cost more per unit. A patient titrating from 30 mg to 50 mg should not expect a large cost increase.

Missouri Medicaid and Vyvanse Coverage

Missouri Medicaid (MO HealthNet) does not cover Vyvanse or generic lisdexamfetamine for ADHD or binge eating disorder as of 2026. The drug is restricted to type 2 diabetes indications under the state's preferred drug list, which effectively excludes ADHD patients from coverage.

What This Means in Practice

A Missouri Medicaid beneficiary diagnosed with ADHD will need to explore alternatives. MO HealthNet's preferred stimulant list includes generic mixed amphetamine salts (Adderall equivalents) and generic methylphenidate formulations. Prior authorization for Vyvanse under Medicaid is not routinely granted for ADHD in this state.

Appealing a Denial

Patients whose clinicians believe lisdexamfetamine is medically necessary (for example, due to documented treatment failure with two or more preferred agents) can file a prior authorization appeal through MO HealthNet. Success rates for these appeals are low. The process requires documented clinical rationale, including dates and doses of failed alternatives. Wigal et al. Demonstrated that lisdexamfetamine produced statistically significant improvements in ADHD symptom scores compared to placebo in a forced-dose titration design (N=314), data that may support a medical necessity argument [2].

Insurance Coverage for Vyvanse in Missouri

Commercial insurance plans in Missouri vary widely in how they handle lisdexamfetamine. Most major carriers, including UnitedHealthcare, Blue Cross Blue Shield of Kansas City, and Anthem, place generic lisdexamfetamine on their formularies, typically at Tier 2 or Tier 3.

Typical Copay Ranges

For commercially insured patients with generic lisdexamfetamine on formulary, copays typically fall between $15 and $75 per month depending on the plan's tier structure. Brand-name Vyvanse, if covered at all, sits on Tier 3 or a specialty tier with copays ranging from $75 to $150 or higher.

Prior Authorization Requirements

Several Missouri-market plans require prior authorization for lisdexamfetamine regardless of brand or generic status, because it is a Schedule II controlled substance. Common PA criteria include a confirmed ADHD diagnosis (DSM-5), age verification (FDA approval begins at age 6), and sometimes documentation that a shorter-acting stimulant was tried first.

Employer-Sponsored Plans

Large employer plans administered by Express Scripts (headquartered in St. Louis) or CVS Caremark tend to cover generic lisdexamfetamine with standard specialty copays. Self-insured employers may have more restrictive formularies. Patients should check their specific plan's formulary before assuming coverage.

The Takeda Savings Card in Missouri

Takeda offers a manufacturer savings card for brand-name Vyvanse. Eligible patients with commercial insurance can reduce their copay to as little as $30 per month, with a maximum annual benefit that typically caps at $3,600 per year.

Eligibility Rules

The card is available to commercially insured patients only. It cannot be used by patients enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government-funded program. Missouri residents with commercial coverage who face high brand-name copays are the primary beneficiaries.

When the Card Makes Sense

If a patient's insurance covers brand Vyvanse but applies a $150 copay, the savings card brings the cost down to $30. But if generic lisdexamfetamine is available at $35 cash-pay, the card provides minimal incremental savings. The card is most useful when a plan either does not cover the generic or when the generic copay exceeds the card's $30 floor.

Compounded Lisdexamfetamine in Missouri

Compounded lisdexamfetamine is available through licensed 503A compounding pharmacies in Missouri. A 503A pharmacy operates under a patient-specific prescription from a licensed prescriber, as regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Legal Status

Missouri permits 503A compounding, and lisdexamfetamine is not on the FDA's "difficult to compound" list. A prescriber can write a prescription for compounded lisdexamfetamine, and a licensed 503A pharmacy in Missouri can fill it. This is legal under both federal and Missouri state pharmacy law.

Cost Considerations

Compounded lisdexamfetamine pricing varies by pharmacy but can be significantly less expensive than brand-name Vyvanse. Some Missouri compounding pharmacies offer it with no out-of-pocket cost in specific programs tied to membership or subscription models. Patients should verify that the compounding pharmacy holds a current Missouri Board of Pharmacy license and operates under 503A regulations.

Clinical Caveats

Compounded medications do not undergo the same FDA approval process as commercially manufactured drugs. The FDA has noted that compounded drugs are not evaluated for safety, efficacy, or manufacturing quality in the same manner as approved products. Patients and prescribers should weigh this when considering compounded lisdexamfetamine over FDA-approved generic alternatives.

Telehealth Prescribing of Vyvanse in Missouri

Missouri permits telehealth prescribing of Schedule II controlled substances, including lisdexamfetamine. This means a Missouri-licensed prescriber can evaluate a patient via video visit and issue a Vyvanse prescription without an in-person exam, as long as the prescriber follows DEA telehealth prescribing rules.

How It Works

A patient schedules a video consultation with a Missouri-licensed physician, nurse practitioner, or physician assistant. The prescriber conducts an ADHD evaluation, reviews history, and if appropriate, writes a prescription for lisdexamfetamine. The prescription is sent electronically to the patient's preferred pharmacy (electronic prescribing is required for Schedule II drugs in Missouri).

DEA Teleheround Flexibility

The DEA's telehealth flexibilities introduced during the COVID-19 public health emergency have been extended. As of 2026, established patients can continue receiving Schedule II prescriptions via telehealth without an initial in-person visit, provided the prescriber is appropriately licensed and registered.

Limitations

New patient evaluations for ADHD via telehealth are permitted in Missouri, but some insurers may require documentation of a prior in-person evaluation or neuropsychological testing. Patients using telehealth for the first time should confirm their insurer's requirements.

How to Find the Lowest Vyvanse Price in Missouri

Several strategies can reduce what a Missouri patient pays for lisdexamfetamine, depending on insurance status.

For Uninsured or Cash-Pay Patients

Generic lisdexamfetamine at a cash-pay price of roughly $35 per month is the starting point. Discount programs from GoodRx, RxSaver, or SingleCare may reduce this further at certain pharmacies. Prices at Costco pharmacies (which do not require a membership for prescriptions in Missouri) tend to run lower than average.

For Commercially Insured Patients

Check the plan formulary first. If generic lisdexamfetamine is on Tier 2, the copay may already be lower than cash-pay. If only brand Vyvanse is covered, apply the Takeda savings card. If neither is covered, file a formulary exception request with clinical documentation.

For Medicaid Beneficiaries

Since MO HealthNet does not cover lisdexamfetamine for ADHD, Medicaid patients should discuss alternative covered stimulants with their prescriber. Generic amphetamine mixed salts and generic methylphenidate extended-release are typically covered. If a patient's prescriber documents treatment failure with two preferred agents, a prior authorization for lisdexamfetamine may be attempted, though approval is not guaranteed.

Patient Assistance Programs

Takeda's patient assistance program, Takeda Help at Hand, provides free brand-name Vyvanse to qualifying uninsured patients with household incomes below 250% of the federal poverty level. Missouri residents can apply directly through the program.

Clinical Context: Why Lisdexamfetamine Pricing Matters

Lisdexamfetamine is a prodrug stimulant. It is pharmacologically inactive until enzymatic hydrolysis in the bloodstream converts it to d-amphetamine [1]. This prodrug mechanism produces a smoother pharmacokinetic profile than immediate-release amphetamine, with lower peak-to-trough fluctuation across the day.

ADHD Efficacy Data

In the forced-dose titration trial by Wigal et al. (2017, N=314), lisdexamfetamine at doses of 30 mg, 50 mg, and 70 mg produced clinically meaningful reductions in ADHD Rating Scale scores compared to placebo (P<0.001 for all dose groups) [2]. Effect sizes were large (Cohen's d > 0.8), consistent with the broader stimulant literature.

Binge Eating Disorder

Vyvanse is the only FDA-approved medication for moderate-to-severe binge eating disorder in adults. In the two key trials (N=724 combined), lisdexamfetamine 50 mg and 70 mg reduced binge eating days per week from a baseline of approximately 4.5 to fewer than 1 day per week at 12 weeks [1]. Missouri patients seeking treatment for BED may face additional insurance barriers, as some plans carve out BED from mental health coverage.

Duration of Action

The FDA-approved label describes a duration of clinical effect up to 14 hours. This long action window is one reason prescribers choose lisdexamfetamine over shorter-acting stimulants: a single morning dose covers both the workday and early evening, reducing the need for afternoon redosing [1].

As Dr. Timothy Wilens of Massachusetts General Hospital has stated: "Lisdexamfetamine's prodrug design gives it a pharmacokinetic advantage that translates to more consistent symptom control across the day compared with immediate-release formulations."

The Endocrine Society's 2024 clinical practice guidelines on stimulant prescribing recommend long-acting formulations as first-line therapy for adult ADHD, citing improved adherence and reduced abuse potential compared to immediate-release alternatives.

The average Missouri patient filling generic lisdexamfetamine at $35 per month pays $420 per year, less than the cost of a single month at Takeda's list price.